Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation

HIV Medicine

Volumn 14, Issue 8, 2013, Pages 463-471

  Patel, N ^a   Veve, M ^a   Kwon, S ^b   Mcnutt, L A ^c   Fish, D ^b   Miller, Cd ^d  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c UNIVERSITY AT ALBANY   (United States)

^d SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Drug interactions; Electrocardiogram; QTc prolongation

Indexed keywords

ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATYPICAL ANTIPSYCHOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DARUNAVIR; ERYTHROMYCIN; METHADONE; PROTEINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; ELECTROCARDIOGRAPHY MONITORING; FEMALE; GASTROESOPHAGEAL REFLUX; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION;

DRUG INTERACTIONS; ELECTROCARDIOGRAM; QTC PROLONGATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FEMALE; GASTROESOPHAGEAL REFLUX; HEPACIVIRUS; HIV INFECTIONS; HUMANS; HYPERTENSION; LONG QT SYNDROME; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TORSADES DE POINTES; YOUNG ADULT;

EID: 84881318292     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12031     Document Type: Article

References (35)

1. Marzolini C, Back D, Weber R etal. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66: 2107-2111.
2. Summary report from the human immunodeficiency virus and aging consensus project: treatment strategies for clinicians managing older individuals with the human immunodeficiency virus. J Am Geriatr Soc 2012; 60: 974-979.
3. Kilborn MJ, Woosley RL. Registry for torsades de pointes with drug treatment exists. BMJ 2001; 322: 672-673.
4. Yap YG, Camm J. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation. BMJ 2000; 320: 1158-1159.
5. Luthi B, Huttner A, Speck RF, Mueller NJ. Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir. Eur J Clin Microbiol Infect Dis 2007; 26: 367-369.
6. Ly T, Ruiz ME. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin Infect Dis 2007; 44: e67-e68.
7. Zhang X, Jordan P, Cristea L etal. Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants. J Clin Pharmacol 2012; 52: 520-529.
8. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366: 1881-1890.
9. Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T. QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol 1987; 59: 376-377.
10. Wiener I, Rubin DA, Martinez E, Postman J, Herman MV. QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration. Mt Sinai J Med. 1981; 48: 53-55.
11. Tholakanahalli VN, Potti A, Hanley JF, Merliss AD. Fluconazole-induced torsade de pointes. Ann Pharmacother 2001; 35: 432-434.
12. Patel N, Abdelsayed S, Veve M, Miller CD. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Ann Pharmacother 2011; 45: 317-324.
13. Flockhart DA, Oesterheld JR. Cytochrome P450-mediated drug interactions. Child Adolesc Psychiatr Clin N Am 2000; 9: 43-76.
14. Del Rosario ME, Weachter R, Flaker GC. Drug-induced QT prolongation and sudden death. Mo Med 2010; 107: 53-58.
15. Dapro B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J 2001; 3 (Suppl K): K70-K80.
16. van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol 2009; 67: 347-354.
17. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335: 290-291.
18. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532-1536.
19. Shah RR. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam Clin Pharmacol 2002; 16: 147-156.
20. Li EC, Esterly JS, Pohl S, Scott SD, McBride BF. Drug-induced QT-interval prolongation: considerations for clinicians. Pharmacotherapy 2010; 30: 684-701.
21. van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010; 70: 16-23.
22. Charbit B, Rosier A, Bollens D etal. Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study. Br J Clin Pharmacol 2009; 67: 76-82.
23. Reinsch N, Buhr C, Krings P etal. Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: results of the HIV-HEART study. HIV Clin Trials 2009; 10: 261-268.
24. Chinello P, Lisena FP, Angeletti C, Boumis E, Papetti F, Petrosillo N. Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients. J Infect 2007; 54: 597-602.
25. Sani MU, Okeahialam BNQ. Tc interval prolongation in patients with HIV and AIDS. J Natl Med Assoc 2005; 97: 1657-1661.
26. Haahr M. Random.org-list randomizer. Dublin. 1998. Available at www.random.org (accessed 10 January 2011).
27. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-1022.
28. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes. Prescrire Int 2009; 18: 104.
29. Saquinavir: prolongation of PR and QT intervals. Prescrire Int 2011; 20: 17.
30. Committee for Proprietary Medicinal Products. Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Non-cardiovascular Medicinal Products. London, UK, Committee for Proprietary Medicinal Products, 1997.
31. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003; 157: 940-943.
32. Shimabukuro-Vornhagen A, Rybniker J, Zoghi S etal. Acquired long QT syndrome and torsade de pointes associated with HIV infection. Case Report Med 2010; 2010: 1-2.
33. Soliman EZ, Lundgren JD, Roediger MP etal. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 2011; 25: 367-377.
34. Miller CD, El-Kholi R, Faragon JJ, Lodise TP. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacotherapy 2007; 27: 1379-1386.
35. Nordin C, Kohli A, Beca S etal. Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients. J Electrocardiol 2006; 39: 199-205.